Halozyme price target raised to $61 from $60 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme Therapeutics to $61 from $60 and keeps a Buy rating on the shares. The analyst says the Darzalex sales ramp will continue driving Enhanze royalty revenue growth near-term.